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Abstract Early detection of mucopolysaccharidosis (MPS)
is an important factor in treatment success; therefore, good
disease biomarkers are vital. We evaluate heparin cofactor
II-thrombin complex (HCII-T) as a biomarker in serum and
dried blood spots (DBS) of MPS patients. Serum HCII-T
and urine dermatan sulphate:chondroitin sulphate (DS:CS)
ratio are also compared longitudinally against clinical
outcomes in MPSI, II and VI patients following treatment.
Samples were collected from MPS patients at the Royal
Manchester Children’s Hospital. DS:CS ratio was obtained
by measuring the area density of spots from 2D electro-
phoresis of urinary glycosaminoglycans. Serum and DBS
HCII-T was measured by sandwich ELISA. Serum HCII-T
is elevated approximately 25-fold in MPS diseases that
store DS, clearly distinguishing untreated MPSI, II and VI
patients from unaffected age-matched controls. Serum
HCII-T is also elevated in MPSIII, which leads to storage
of heparan sulphate, with an increase of approximately 4-
fold over unaffected age-matched controls. Urine DS:CS
ratio and serum HCII-T decrease in response to treatment of
MPSI, II and VI patients. HCII-T appears to respond
rapidly to perturbations in treatment, whilst DS:CS ratio
responds more slowly. HCII-T is a suitable biomarker for
MPSI, II and VI, and it may also be informative for MPS
diseases storing HS alone, such as MPSIII, although the
elevation observed is smaller. In treated MPS patients,
HCII-T and DS:CS ratio appear to measure short-term and
long-term treatment outcomes, respectively. The potential
value of HCII-T measurement in DBS for newborn
screening of MPS diseases warrants further investigation.
Introduction
Mucopolysaccharide (MPS) diseases are lysosomal storage
disorders in which deficiencies of glycosaminoglycan
(GAG)-degrading enzymes lead to excessive GAG accu-
mulation in cells and tissues. Various combinations of the
GAGs heparan sulphate (HS), dermatan sulphate (DS),
keratan sulphate (KS) and chondroitin sulphate (CS) are
accumulated, depending on the lysosomal enzyme deficien-
cy. Phenotypic variability between types of MPS is caused
by mutations in different lysosomal enzymes, and variabil-
ity in symptoms within each type of MPS is due to different
levels of residual enzyme activity. Progressive cognitive
impairment is a significant feature of severe MPSI Hurler
(IH), II, III and VII, whilst dysostosis multiplex and facial
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dysmorphia can be presenting features of MPSI, II, IV, VI
and VII. Attenuated MPSI, II, III and VII may not show
significant neurological involvement until late into the
course of the illness. Organomegally, respiratory insuffi-
ciency, cardiac compromise and joint problems can greatly
affect daily life of MPSI, II and VI patients whilst
behavioural disturbances are common in severe MPSII
and III patients (Wraith et al. 2004; Meyer et al. 2007;
Montano et al. 2007; Jones et al. 2009; Decker et al. 2010).
Treatment is available for some MPS diseases: enzyme
replacement therapy (ERT) is currently used to treat MPSI
patients with non-neurological manifestations, as well as for
MPSII and VI (Wraith et al. 2004; Harmatz et al. 2008;
Wraith 2008), whilst haematopoietic stem cell transplanta-
tion (HSCT) has been successfully used to treat MPSIH, VI
and VII (Krivit et al. 1984; Peters et al. 1998; Yamada et al.
1998; Peters and Steward 2003). However, treatments are
less successful in patients with severe neurodegenerative
disease and it is unclear whether treatment can reverse
existing organ damage. It is known that early diagnosis
within the first few months of life and rapid treatment
delivery, such as HSCT before the age of 2 years in MPSIH
patients, is advantageous for successful outcomes in
lysosomal storage disorders (Vellodi et al. 1997; Krivit
2002; Meikle and Hopwood 2003; Escolar et al. 2005;
Boelens et al. 2009). Therefore, biomarkers that can be
used for early diagnosis of MPS and monitoring treatment
outcome are important in effective disease management.
Currently, in the clinic, a diagnosis of MPS is confirmed
using both urinary GAG analysis and blood levels of the
deficient enzyme. However, these methods are time
consuming and expensive. Blood enzyme levels are
inappropriate for monitoring disease progression once the
deficient enzyme is being supplied by treatment with ERT
as these levels can fluctuate considerably, whilst urinary
GAG levels can give variable outcomes as results vary with
age and hydration state of the patient. In Manchester, it has
been determined that, for MPS diseases in which DS
accumulates, the ratio of DS to a GAG that is not stored,
such as CS in the urine (the DS:CS ratio), is a good
predictor of metabolic outcome (Church et al. 2007), and is
a superior biomarker to measurement of total urinary GAG.
Urine DS:CS ratio has been shown to closely correlate with
blood enzyme level in MPSI patients following treatment,
and indicates a better metabolic outcome in patients
receiving HSCT compared to those receiving ERT alone
(Wynn et al. 2009).
Heparin cofactor II-thrombin complex (HCII-T) was
identified as a biomarker for MPS diseases by Randall et al.
(2006, 2008), and we recently evaluated this biomarker in
murine models of MPS (Langford-Smith et al. 2010). In
mice, HCII-T is a reliable biomarker for MPSI, but not
MPSIIIA and IIIB (Langford-Smith et al. 2010). In vitro
and in vivo data suggest that this is because HCII-T
formation is increased in the presence of DS, which is
stored in MPSI, but not in the presence of HS, which is
stored in MPSIII. Here, we extend our investigation to
patient samples of MPSI, II, IIIA, IIIB, IIIC, IV and VI,
showing that HCII-T is indeed a reliable biomarker for
those MPS diseases in which DS accumulates, and to a
lesser extent also for those that accumulate HS. We also
compare the HCII-T biomarker against urine DS:CS ratio
for monitoring treatment outcomes and show that both
biomarkers decrease during successful treatment, but that
HCII-T responds more rapidly to perturbations in treatment.
Materials and methods
Patient diagnosis
Diagnosis of MPS was achieved by demonstration of
elevated urinary GAGs, and enzyme activity below 10%
of the lower limit of the normal range. Clinical symptoms
and mutation analysis were used to diagnose severity of the
disease.
Blood sample collection
Blood samples were collected by clean venepuncture and
were not taken from a central line. Serum was collected
from blood without anticoagulant which was allowed to
clot for 30 min at room temperature, and then centrifuged at
3,000g for 10 min at room temperature. Serum was stored
at −80°C. Dried blood spots (DBS) were collected on
Guthrie cards (Whatman), allowed to dry for 4 h at room
temperature, and then stored at 4°C. Serum and DBS
samples were collected from MPS patients undergoing
blood sampling at the Royal Manchester Children’s
Hospital and from other MPS patients within the UK.
Control serum and DBS samples were collected from
patients undergoing blood tests for unrelated investigations
at the Royal Manchester Children’s Hospital. The study
was ethically approved under REC 08H101063.
Measurement of heparin cofactor II-thrombin (HCII-T)
complex
The HCII-T complex was quantified using a sandwich
ELISA as described previously (Randall et al. 2008;
Langford-Smith et al. 2010). A polyclonal anti-thrombin
capture antibody and polyclonal anti-HCII detection anti-
body (Affinity Biologicals) were used. DBS samples were
prepared by punching a 3-mm-diameter sample from the
Guthrie card using a Wallac DBS Puncher (DELFIA) and
were eluted with 200 μl General Purpose Serum Diluent
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(Serotec) for 80 min at room temperature. Standards, serum
and DBS samples were diluted in General Purpose Serum
Diluent; serum up to 25,000-fold, DBS up to 20-fold. All
standards and samples were assayed in duplicate, with
serum samples tested at three different dilutions each and
DBS samples tested at two or three dilutions each. A 1-μM
HCII-T standard was made by reaction of human thrombin
and human heparin cofactor II (Enzyme Research Labora-
tories) in the presence of 0.05 U/ml heparin. This was used
to make a series of standards from 1 to 1,500 pM, the linear
range of which was used as the standard curve.
Measurement of urinary glycosaminoglycans (GAGs)
Total urinary GAGs were measured using dimethyl meth-
ylene blue. Urine substrate was measured as the DS:CS
ratio, as described previously (Church et al. 2007). Urine
DS:CS ratio was obtained by measuring area density of
spots from two-dimensional electrophoresis of extracted
GAGs.
Delivery of KS to mice and serum sampling
Wild-type (WT) mice from an MPSIIIB colony were
maintained as described (Canal et al. 2010; Malinowska et
al. 2009). KS (160 ug) (AMS Biotechnology) was delivered
via tail vein injection to WT mice and serum sampled after
30 min as described in a similar series of experiments
conducted previously with HS and DS (Langford-Smith et
al. 2010).
Statistical analysis
For statistical analysis, one extreme outlier from the unaffect-
ed serum group was formally removed using the boxplot tool
in SPSS (extreme outliers are defined as those more than 3×
the interquartile range outside of the interquartile box). No
other groups were affected. Data were analysed using one-
way ANOVA, applying Tukey’s multiple comparisons test as
a post hoc comparator. Where appropriate, data were log
transformed to normalise data prior to statistical analysis.
Significance was assumed where p values were less than 0.05
of a studentised range of Q.
Ethical approval
Ethical review for these studies was performed and
approved by The University of Manchester, Central Man-
chester University Hospitals NHS Foundation Trust, and
the North West Research Ethics Committee on REC
08H101063. Written informed consent was obtained from
the parents or guardians of the children involved for all
samples taken.
Results
Serum HCII-T is elevated in MPSI, II, III and VI patients
Serum samples were collected from untreated MPS patients
and unaffected age-matched controls as well as HSCT-treated
MPSI patients who received transplants 1–16 years ago.
HCII-T is very significantly increased in MPSI, II and VI
patients compared to unaffected individuals or treated MPS I
patients (p<0.001) (Fig. 1a). The measurement ranges of
HCII-T for MPSI (61.1–325.0 nM), MPSII (156.7–
252.0 nM) and MPSVI patients (149.3–230.3 nM) do not
overlap with unaffected age matched controls (5.0–11.0 nM)
or HSCT treated MPSIH patients (6.2–37.9 nM). On
average, MPSI, II and VI patients have HCII-T levels that
are approximately 25-fold higher than unaffected controls.
There is no significant difference between the unaffected
group and the treated MPSI patient group, though some
treated patients still lie above the range of the unaffected
group (Table 1). This suggests that serum HCII-T levels are
normalised in some MPSI patients receiving HSCT, and are
close to the normal range in others.
In serum samples from patients with MPSIIIA (n=8),
IIIB (n=7) and IIIC (n=2) there are no significant differ-
ences between HCII-T levels of the individual subtypes.
HCII-T levels of all MPSIII patients are significantly
elevated compared to unaffected controls or treated MPSIH
patients (p<0.02), although the elevation is not as extreme
as MPSI, II and VI samples, with average HCII-T levels
being approximately 4-fold higher than unaffected controls
(Fig. 1a). All but one of the MPSIII values (7.3–91.5 nM)
lie outside the range of the unaffected group. Based on our
previous work, which showed that injection of DS, but not
HS, leads to elevation of HCII-T in WT mice, it is clear that
DS has a greater effect on HCII-T complex formation than
HS. However, storage of HS in MPSIII patients does have
an effect on HCII-T, which is sufficient to distinguish
MPSIII patients from unaffected controls.
In a single sample from an untreated MPSIV patient
storing KS, the serum HCII-T value (14.8 nM) lies slightly
above the unaffected range (Fig. 1a). Further patients would
be necessary to determine if this slight elevation would
reliably allow distinction of MPSIV patients using this
method.
DS affects HCII-T complex formation much more than HS
or KS
In our murine work, we determined the effect of intravenous
infusion of HS or DS to normal WT mice, showing that only
DS produced a significant serum elevation of HCII-T
(Langford-Smith et al. 2010). To determine if KS, stored in
MPSIV, could mediate HCII-T complex formation, we also
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Fig. 1 Ability of the HCII-T biomarker to distinguish between MPS
patients and unaffected age matched controls. a Serum HCII-T was
significantly higher (*p<0.001) in MPSI (n=9) (■), MPSII (n=3) (◊)
and MPSVI (n=2) (●) patients compared to unaffected controls (n=8)
(Δ) and treated MPSI patients (n=20) (□). HCII-T is significantly
elevated, albeit to a lesser extent in MPSIII (n=17) (○) and only
slightly in MPSIV (n=1) (▲). b DBS HCII-T levels in all MPS
samples that had been stored at −20°C were below levels of unaffected
DBS samples that had been stored at 4°C, demonstrating that freezing
DBS samples is likely to lead to degradation of the HCII-T complex. c
DBS HCII-T levels decrease over time when DBS are stored at room
temperature in both samples from MPSI patients (n=2) (■) and
unaffected controls (n=1) (Δ). d DBS HCII-T levels in MPSI patients
(n=4) (■) were significantly greater (*p<0.005) than those of
unaffected controls (n=6) (Δ) and treated MPSI patients (n=6) (□).
A small number of samples indicate that DBS HCII-T is only slightly
elevated in MPSIII (n=2) (○) and MPSIV patients (n=1) (▲). Error
bars represent standard deviations about the mean
Table 1 Serum and blood spot levels in unaffected and affected patients
Serum [HCII-T] (nM) Blood spot [HCII-T] (pM)
Mean ± SD Mean age (years) (range) n Mean ± SD Mean age (years) (range) n
Unaffected 8.0±2.1 8.8 (1.0–19.5) 8 71±33 7.2 (1.9–12.0) 6
MPSI post-HSCT 16.7±10.3 7.6 (2.3–16.4) 20 78±37 5.3 (1.0–10.6) 6
MPSI 176.2±81.1 2.1 (0.3–10.9) 9 667±470 3.2 (0.4–10.9) 4
MPSII 212.0±49.5 2.4 (1.5–4.1) 3
MPSIII 32.1±22.1 12.6 (2.7–35.0) 17 107±83 8.3 (6.9–9.7) 2
MPSIV 14.8 2.5 1 132 2.5 1
MPSVI 189.8±57.3 0.6 (0.61–0.64) 2
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Table 2 The diagnosis, age of presentation, presenting symptoms, treatments and clinical outcomes for MPS patients involved in the longitudinal
study of HCII-T and DS:CS ratio
Patient Diagnosis Age of
presentation
Presenting symptoms Treatment Clinical outcomes










Developed the ability to walk unaided
Worsening thoracolumbar kyphosis
B MPSIH 5 months Coarse facial features, spinal gibbus,
hepatosplenomegaly, respiratory








Respiratory symptoms improving but
recurrent chest infections possibly




Progressive bone and joint
disorders, severe scoliosis,







C MPSIH 7 years Joint stiffness, hepatosplenomegaly,
facial dysmorphia, corneal haze,
sleep apnoea, kyphosis, scoliosis







with mild mitral regurgitation
Hepatosplenomegaly
drastically reduced
Improvements in breathing and mobility








increased from 11 to 25%
E MPSII 4 years Large head, coarse facial features,
moderate developmental delay,





alertness and ease of movement
Improved hearing, motor development
Lack of sleep apnoea
Mild mitral regurgitation
Physiotherapy scores improved from
moderate to mild range








Improvements in speech and language




G MPSVI 6 months Curvature of the spine, cardiac






Desaturation in sleep study, nasal




Improved posture and walking ability
H MPS VI 7 months Gibbus and pectus excavatum
deformities, reduced hearing
on one side, noisy breathing
and recurrent respiratory infections,
soft systolic heart murmur
ERT from diagnosis
(Naglazyme)
Normal cardiac function, no heart
murmur
Stopped snoring, tonsils
smaller and nose clear
Hearing appears normal
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injected equivalent amounts of KS (160 μg) intravenously
into WT mice and monitored serum and DBS HCII-T levels
30 min after infusion. No changes in HCII-T levels were
seen after infusion of exogenous KS, suggesting that KS
does not mediate significant HCII-T complex formation and
thus that HCII-T may not reliably diagnose MPSIV.
HCII-T deteriorates in improperly stored dried blood spots
We previously determined that measurement of HCII-T in
fresh DBS samples from MPSI mice gave better separation
between the MPSI and unaffected groups compared to
serum HCII-T (Langford-Smith et al. 2010). We therefore
measured HCII-T in archived patient DBS samples stored at
−20°C to determine if it was possible. HCII-T levels are
near the lower limit of detection for the ELISA, and HCII-T
was not elevated above the unaffected range in any patient
samples suggesting that the complex has deteriorated by
freezing (Fig. 1b). We then tested DBS samples before and
after storage at room temperature for several months, and
show that HCII-T values decline, giving much lower values
than the original HCII-T levels (Fig. 1c). In all subsequent
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work, we have only used DBS stored at 4°C as we have
previously shown that HCII-T can be detected reliably in
DBS samples that have been stored for up to a year at 4°C
(Langford-Smith et al. 2010).
Dried blood spot HCII-T is significantly elevated in MPSI
patients
HCII-T was measured in DBS samples from MPS patients
and age matched unaffected controls that had been stored at
4°C. No samples were available for MPSII or VI. DBS
HCII-T is significantly elevated in untreated MPSI patients
compared to unaffected controls or HSCT treated MPSI
patients (p<0.005) (Fig. 1d). This suggests that measure-
ment of HCII-T in appropriately stored DBS can be used to
distinguish MPSI patients, although more patient samples
would be necessary to be sure of this trend. As with the
serum data, the mean and range of the unaffected group
(71 pM, 22–100 pM) and treated MPSI patients (78 pM,
37–128 pM) are very similar, with no significant difference
between the groups. The range of the MPSI group (132–
1272 pM) does not overlap with either the unaffected group
or treated MPSI patients. The single MPSIIIA and MPSIV
DBS samples showed slight HCII-T elevation over base-
line, although with only one patient it is hard to know if this
is artefact or real effect.
HCII-T and DS:CS ratio both respond to treatment
and correlate with clinical outcomes
Serum HCII-T and urine DS:CS ratio were measured
longitudinally in four MPSI, two MPSII and two MPSVI
patients (Table 2) and compared against clinical measures of
treatment response. In these patients, both biomarkers are
elevated above unaffected controls before treatment, and
both biomarkers decrease gradually following treatment with
ERT alone for MPSII and VI patients, or with ERT and
HSCT for MPSI patients (Fig. 2a–g). HCII-T values
fluctuate more over time than the urine DS:CS values,
though the overall trend in both biomarkers is a decrease
towards normal levels. In some cases, the serum HCII-T
biomarker reaches the normal range of 5.0–11.0 nM, whilst
the urine DS:CS biomarker decreases but remains above
baseline in treated MPS patients compared to unaffected
individuals who do not have detectable DS in their urine,
making the unaffected DS:CS ratio 0. The greater fluctuation
of the HCII-T biomarker suggests a rapid response to
changes in treatment, which may indicate short-term effects
such as minor illness, antibody responses or perturbations in
the course of treatment. We suggest that the steadier decline
of urinary DS:CS ratio is more indicative of long-term
treatment outcomes. Both biomarkers appear to be useful in
assessing a patient’s response to treatment; however, the
following case reports highlight some of the advantages of
the HCII-T biomarker (Table 2 details presenting symptoms).
Patient A presented with MPSIH and was treated with
ERT and subsequently HSCT. Serum HCII-T and urine DS:
CS biomarkers decreased, but when treatment with ERT
ended we observe a large increase in HCII-T (Fig. 2a-1).
This suggests that in this patient the withdrawal of ERT was
followed by short-term reduction in enzyme, leading to
increased circulating DS, whilst the transplanted cells were
established. Clinical assessments at 11 and 16 months post-
transplant showed improvement in several areas, including
mobility, hearing and speech (Fig. a-2). By this stage,
serum HCII-T was within the normal range and urine DS:
CS continued to decrease (Fig. 2a-3). Both biomarkers
appear to correlate with an improvement in clinical
symptoms.
Patient B presented with MPSIH and was treated with
ERT, HSCT, autologous HSCT rescue, followed by further
Fig. 2 Response of serum HCII-T and urine DS:CS ratio biomarkers
to treatment. Grey shading represents periods of ERT. The dashed line
represents the upper limit of the range of serum HCII-T values in
unaffected age-matched controls. DS is not detected in the urine of
unaffected individuals; therefore, the urine DS:CS ratio for unaffected
controls is 0. Patient presentation data is detailed in Table 2. a Patient
A has MPSIH. Serum HCII-T and urine DS:CS decrease in response
to treatment, although following withdrawal of ERT there is a large
increase in HCII-T and DS:CS levels off (1). The patient has improved
development but worsening thoracolumbar kyphosis (2). The patient
has stopped wearing hearing aids, developed the ability to walk
unaided and has shown improvements in speech and language (3).
After HSCT, the patient’s alpha-iduronidase activity is within the
normal range (3). b Patient B has MPSIH and received 2 courses of
ERT and 2 transplants due to failure of the first HSCT. During the
unsuccessful transplant, autologous rescue and ERT, serum HCII-T
levels fluctuated, but following the report of successful engraftment
(4), HCII-T and urine DS:CS ratio have decreased. c Patient C has
MPSIH and received ERT, leading to a decrease in both serum HCII-T
and urine DS:CS levels. d Patient D has MPSIH and has been treated
with ERT, resulting in a decrease in both biomarkers. e Patient E has
MPSII and has been receiving ERT since 1 month after diagnosis,
leading to an overall decrease in serum HCII-T and urine DS:CS
levels. A large increase in serum HCII-T occurred when the patient
was experiencing cheek flushing during enzyme infusions (5). This
patient still has mild mitral regurgitation (6), but physiotherapy scores
have improved from the moderate range (6) to the mild range (7). f
Patient F has MPSII and has decreasing levels of serum HCII-T and
urine DS:CS following treatment with ERT. A small increase in HCII-
T occured when cheek flushing was observed during enzyme infusions
(8). Speech and language were mildly delayed (9), but over time this
improved (10), as well as increased mobility, exercise tolerance, and a
lack of hepatosplenomegaly or joint stiffness (10). g Patient G has
MPSVI and has been receiving ERT since diagnosis, but the initial
decrease in serum HCII-T has not been maintained. The patient had
desaturation during a sleep study, nasal obstruction and large tonsils
(11). Mitral valve regurgitation has progressed from mild–moderate to
moderate–severe (12). However, posture and walking ability have
improved, and the patient has received cast management for the
curved spine (13). h Patient H has MPSVI and received ERT, leading
to a decrease in both serum HCII-T and urine DS:CS levels
R
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ERT and a second HSCT. The HCII-T biomarker fluctuates,
with increases in HCII-T at the end of each phase of ERT.
Both serum HCII-T and urine DS:CS ratio decrease after
the second HSCT when successful engraftment had been
reported (Fig. 2b-4).
Patients C and D presented with MPS IH and have
received ERT for 3–4 months to date. During this time,
their initially high serum HCII-T and urine DS:CS levels
have decreased, correlating with clinical improvement
(Fig. 2c, d).
Patient E presented with MPSII and received ERT
treatment. No significant infusion associated reactions were
observed apart from occasional cheek flushing. Cheek
flushing during infusion may indicate a hypersensitivity
response and corresponds with marked increases in the
HCII-T levels. Although the patient tested negative for IgG
and IgE antibodies against the enzyme, something is
interfering with the success of ERT at clearing blood DS
at this time (Fig. 2e-5). HCII-T levels soon returned to near
normal and a clear clinical improvement was noted,
including increased energy levels, alertness, and ease of
movement, as well as improved hearing, motor develop-
ment and no sleep apnoea (Fig. 2e-6, 7). Both biomarkers
decreased over this time, correlating with an improvement
in clinical symptoms (Fig. 2e).
Patient F presented with MPSII and received ERT
treatment. Acute elevations in serum HCII-T also appear
to correlate with illness and observations of cheek flushing
during enzyme infusions (Fig. 2f-8). The patient still had
mildly delayed speech and language 7 months after ERT
began (Fig. 2f-9), but this is consistent with hearing loss,
and after 1 year of treatment with ERT speech was reported
to be improved (Fig. 2f-10) correlating with decreased
serum HCII-T and urine DS:CS.
Patient G presented with MPSVI and received ERT
treatment. Initially, a decrease in serum HCII-T and urine
DS:CS was observed, but then HCII-T began to increase and
has remained high up to 1 year after treatment began (Fig. 2g).
This patient has an increasing trend of anti-Naglazyme IgG
antibodies, with a titre of 2,430 at 78 days post-diagnosis and
a titre of 7,290 at 177 days post-diagnosis (Figs. 2g-11, 12).
Further antibody titres are not available at this time, though if
anti-Naglazyme IgG production continues these antibodies
may inhibit treatment success. The patient is routinely treated
with paracetamol for high temperatures during enzyme
infusions, suggesting that a hypersensitivity response may
be present when enzyme is delivered.
Patient H presented with MPSVI and received ERT
treatment. During the first 24 weeks of ERT, serum HCII-T
and urine DS:CS ratio have decreased, with serum HCII-T
reaching normal levels (Fig. 2h). This correlates with
improved clinical condition including a return to normal
hearing and cardiac function.
Discussion
We have demonstrated that serum and DBS HCII-T is
elevated in patients storing dermatan sulphate—namely
those with MPSI, II and VI, which is very much in
agreement with our previous observations in the mouse
models of MPS disease (Langford-Smith et al. 2010). We
also expect that HCII-T would be elevated in MPSVII
patients who store DS, but this disease is rare, and patient
samples were not available to test this hypothesis. Our
serum HCII-T values for unaffected age-matched controls,
as well as MPSI and MPS II patients, fall within the ranges
observed by Randall et al. (2008), supporting the overall
conclusion that HCII-T is elevated in these diseases.
We have also shown that HCII-T is significantly elevated
above unaffected controls in serum from MPSIII patients.
This agrees with work by Randall et al. (2008), who
showed a small elevation above age matched controls in
serum of two MPSIII patients. However, the elevated
values that we observed (7.3–91.5 nM), and those reported
by Randall et al. (32–91 nM) are not very far above the
unaffected controls, particularly when compared to the
elevation observed in MPSI and MPSII patients. Therefore,
HCII-T may not be as reliable a biomarker for monitoring
treatment outcome in MPSIII. In a single sample from an
MPSIV patient, we also see slight elevation above the
unaffected control range (14.8 nM), as do Randall et al. in
one MPSIV patient (27.9 nM). A larger sample size would
be necessary to draw a firm conclusion, but HCII-T may
also be slightly elevated in MPSIV.
This differs from our previous data showing that
intravenous delivery of pathological levels of HS or KS
into WT mice do not result in substantial elevation of the
HCII-T complex in serum or DBS (Langford-Smith et al.
2010). This may be because the mice live a shorter life-span
than patients and thus accumulate less GAGs than patients,
or it could be due to specificity of the antibodies used,
which are directed to human thrombin and human HCII. It
is interesting to note that the average HCII-T values
obtained in patient samples are higher than those in mice
for MPSI (mouse 130.8 nM, human 176.2) and MPSIII
(mouse 16.1 nM, human 32.1 nM), which would support
either theory.
Both serum HCII-T and urine DS:CS ratio are elevated
prior to treatment of MPSI, II and VI patients and decrease in
response to treatment, making both suitable biomarkers for
diagnosis and for monitoring treatment outcomes. However,
the HCII-T biomarker appears to be more responsive to
transient changes such as infusion-related reactions and
withdrawal of ERT following HSCT and correlates well with
clinical observations. This may make HCII-T more informa-
tive when assessing immediate success of treatment whilst
urine DS:CS ratio measurements correlate well with long-term
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clinical outcomes. The rapid response of serum HCII-T is
likely to be because HCII-T complex formation responds
directly to an increase in circulating DS, so when enzyme
levels decrease or enzyme is inhibited by antibodies, the
amount of soluble DS in the blood will increase, having an
immediate effect on HCII-T levels. In comparison, urine DS:
CS ratio is likely to be indicative of renal involvement in the
disease pathology and will respond more slowly to levels of
DS secreted by cells in the renal pathway.
In MPSIH patient A, the increase in HCII-T post HSCT,
immediately following ERT withdrawal, is likely to have
been caused by transient DS elevation in the bloodstream
whilst the donor cells became established and began to
produce sufficient enzyme. Clearly this will vary from
patient to patient and with the enzyme produced from the
donor graft, as we did not observe significant HCII-T
elevations in patient B post-HSCT and ERTwithdrawal, but
HCII-T could be used to monitor this response. Our HCII-T
treatment data also agree with Randall et al. (2008) who
observed a decrease in serum HCII-T in one MPSI patient
receiving ERT followed by HSCT. Interestingly, they
observed an MPSVI patient whose HCII-T levels dropped
initially following ERT, but increased again after 65 weeks
of treatment (Randall et al. 2008). This is very similar to the
trend we observed in MPSVI patient G whose serum HCII-
T levels began rising again at 78 days post-diagnosis
following an initial decrease in response to ERT. The
clinical history of our MPSVI patient suggests that the high
HCII-T levels correlate with elevated IgG antibody levels
and indicate a less satisfactory response to ERT than that
observed in the MPSII patients. It should be noted that,
even if inhibitory antibodies are not detected, it has been
demonstrated in a mouse model of the lysosomal storage
disorder metachromatic leukodystrophy that non-inhibitory
antibodies can have a negative effect on ERT by blocking
uptake of the recombinant enzyme (Matzner et al. 2008).
Our investigations of HCII-T measurement in DBS
samples have shown promising initial data, but further
investigation of DBS HCII-T measurement will be required
in a larger group of patients to determine if these measure-
ments are as reliable as serum HCII-T for diagnosis. This
could in time lead to development of HCII-T for newborn
screening in MPSI, II and VI, which all have available
treatments.
In conclusion, serum HCII-T is a reliable biomarker for
MPS diseases in which DS is stored, including MPSI, II,
and VI and probably also MPSVII, and HS also has a
smaller but still significant effect on HCII-T formation,
with elevation above unaffected controls in MPSIII
patients. The ability to measure HCII-T in DBS may
provide a suitable method for newborn screening for MPS
diseases for which treatments exist. Both serum HCII-T and
urine DS:CS are suitable to track progress of MPSI, II, and
VI patients. Serum HCII-T decreases rapidly in response to
successful treatment with HSCT and/or ERT and elevations
appear to correlate with enzyme infusion reactions or rising
anti-enzyme antibody levels. However, MPSI patients who
have received HSCT 1–16 years ago have HCII-T levels
within or near the normal range; therefore, serum HCII-T is
likely to be a good biomarker for monitoring short-term
treatment outcomes, but may not be suitable to measure
long-term treatment effects. Urine DS:CS is able to
discriminate between different therapies (Wynn et al.
2009) and appears to be more suited for measuring long-
term treatment effects in HSCT patients, but does not
respond as rapidly as HCII-T to perturbations in treatment.
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